Our business model means that we do not have to wait for clinical and regulatory approvals until a finished form of treatment, but can achieve revenue more quickly through development collaborations and licensing deals. The company does not close any doors, but if there are sufficient financial conditions, in-house development of new therapies may be relevant. Our intention is now to intensify our focus to the US market.
CarryGenes has conducted development work in both Sweden and the United States.
